论文部分内容阅读
目的观察评价替吉奥联合奥沙利铂一线治疗进展期胃癌的有效性和安全性。方法 72例组织病理学确诊的进展期胃癌患者随机分为两组,试验组36例患者给予替吉奥联合奥沙利铂方案,对照组36例患者给予mFOLFOX6方案,两组患者于治疗6周后评价疗效及不良反应。结果试验组和对照组的有效率(RR)分别为55.6%和50.0%,临床获益率(DCR)分别为88.9%和86.1%,两组比较差异无统计学意义(P>0.05)。两组主要的不良反应是血液学毒性、胃肠道反应、神经毒性和肝功能损伤,大多数为Ⅰ~Ⅱ度,仅在胃肠道反应方面对照组明显高于试验组,差异有统计学意义(P<0.05),其余不良反应两组比较差异无统计学意义(P>0.05)。结论替吉奥联合奥沙利铂方案一线治疗进展期胃癌近期疗效较好,不良反应较轻,尤其胃肠道反应的发生概率大大降低,该方案值得临床上进一步推广研究和应用。
Objective To evaluate the efficacy and safety of tegaserod combined with oxaliplatin in the treatment of advanced gastric cancer. Methods Seventy-two patients with histopathologically diagnosed advanced gastric cancer were randomly divided into two groups: 36 patients in the trial group received the tegaserod combined oxaliplatin regimen, and 36 patients in the control group received mFOLFOX6 regimen. The two groups were treated for 6 weeks After evaluation of efficacy and adverse reactions. Results The effective rate (RR) of the experimental group and the control group were 55.6% and 50.0% respectively, and the clinical benefit rates (DCR) were 88.9% and 86.1% respectively. There was no significant difference between the two groups (P> 0.05). The main adverse reactions in the two groups were hematological toxicity, gastrointestinal reaction, neurotoxicity and liver function damage, most of which were grade Ⅰ ~ Ⅱ. The control group was significantly higher than that of the test group only in gastrointestinal reactions, with statistical difference (P <0.05). There was no significant difference in other adverse reactions between the two groups (P> 0.05). CONCLUSION: The first-line treatment of advanced gastric cancer with the combination of oxgilli and oxaliplatin is better and the adverse reactions are less, especially the probability of gastrointestinal reaction is greatly reduced. The scheme deserves further clinical application and research.